Subjects: Cost-Benefit Analysis - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Cost-Benefit Analysis ✖

41. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
Subject(s):: Immunotherapy, Adoptive
Leukemia, B-Cell -- drug therapy
Lymphoma, B-Cell -- drug therapy
Lymphoma, Non-Hodgkin -- drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Adult
Child
Clinical Trials as Topic
Clofarabine -- therapeutic use
Cost-Benefit Analysis
Immunotherapy, Adoptive -- adverse effects
Immunotherapy, Adoptive -- economics
Receptors, Chimeric Antigen -- therapeutic use
Treatment Outcome
Humans
United States

42. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
Subject(s):: Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States

43. Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
Subject(s):: Cystic Fibrosis -- drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator -- therapeutic use
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator -- adverse effects
Treatment Outcome
Humans
United States

44. Elagolix for treating endometriosis: final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):: Endometriosis -- drug therapy
Gonadotropin-Releasing Hormone -- antagonists & inhibitors
Analgesics -- adverse effects
Analgesics -- therapeutic use
Cost-Benefit Analysis
Pain -- drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

45. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):: Immunologic Factors -- therapeutic use
Immunomodulation
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Treatment Outcome
Humans
United States

46. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):: Amyloidosis, Familial -- drug therapy
RNA, Small Interfering -- therapeutic use
Amyloid Neuropathies, Familial -- drug therapy
Amyloidosis, Familial -- complications
Clinical Trials as Topic
Cost-Benefit Analysis
RNA, Small Interfering -- adverse effects
RNA, Small Interfering -- economics
Treatment Outcome
Humans
United States

47. Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):: Androgen Antagonists -- therapeutic use
Prostatic Neoplasms -- drug therapy
Androgen Antagonists -- adverse effects
Cost-Benefit Analysis
Disease Progression
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

48. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):: Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Complement C1 Inhibitor Protein -- adverse effects
Complement C1 Inhibitor Protein -- economics
Cost-Benefit Analysis
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

49. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):: Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

50. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018
Subject(s):: Antibodies, Monoclonal -- therapeutic use
Asthma -- drug therapy
Inflammation -- drug therapy
Antibodies, Monoclonal -- adverse effects
Antibodies, Monoclonal -- economics
Biological Therapy
Cost-Benefit Analysis
Hypersensitivity -- drug therapy
Inflammation -- complications
Treatment Outcome
Humans
United States